MP27-16 ORAL RELUGOLIX FOR ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER: DETAILED SAFETY ANALYSIS FROM THE RANDOMIZED PHASE 3 HERO STUDY. (May 2022)